- Category
- Micro (2024-25)
- Udyam number
- UDYAM-MH-18-0003264

Raybros Medicaments Private Limited
About Raybros Medicaments Private Limited
Data last updated:
Raybros Medicaments Private Limited is a private limited company based in Mumbai, Maharashtra, India. It operates in the pharmaceutical retail and distribution segment of the pharmaceuticals sector. It was incorporated on 17 April 2018 and has been in existence for over 8 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U33100MH2018PTC308142. Its GSTIN is 27AAICR8960K1ZN (Maharashtra).
The company has an authorised share capital of ₹1 Lakh and a paid-up capital of ₹1 Lakh. It is led by directors including Sarothi Roy and Madhumita Roy.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Mumbai, Maharashtra.
As per the financials filed for FY 2024, the company reported a revenue of ₹2.74 Cr, a decline of 2% compared to the previous year. For the same year it recorded a net profit of ₹10.79 Lakh (net margin 3.9%) and EBITDA of ₹16.35 Lakh (EBITDA margin 6%). Revenue has grown at a compounded annual rate (CAGR) of 9% over three years.
The company has about 16 employees on its provident fund (EPFO) records.
Raybros Medicaments Private Limited is registered as a micro enterprise under the Udyam registration framework (Reg. No. UDYAM-MH-18-0003264).
Company details
Recognitions & Rankings of Raybros Medicaments
Contact details
Raybros Medicaments Private Limited's registered office is in Mumbai, Maharashtra. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Registered AddressGala No.12 Atlanta Estate Premises Co – Op Soc.Ltd. Vit Bhatti Goregaon Mulund Link Rd Gore, Gaon – East, Mumbai, Maharashtra, India – 400063
- IndustryPharma, Pharmaceutical Retailers & Distributors
To see the full contact details of Raybros Medicaments Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Raybros Medicaments is trade. In detail, this covers wholesale trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of Raybros Medicaments Private Limited, buy the company report.
Financials of Raybros Medicaments Private Limited
FY 2025 filings availableRaybros Medicaments Private Limited reported revenue of ₹2.74 Cr (down 2% YoY) for FY 2024.
Compounded Annual Growth Rate (CAGR)
Revenue fell 2% in the latest year, but over three years it has grown at a compounded annual rate (CAGR) of 9%. EBITDA rose 9% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹16.35 Lakh | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹10.79 Lakh | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 6% | ||||
| Net Profit Margin | 3.9% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Raybros Medicaments Private Limited, buy the company report.
Board of directors of Raybros Medicaments Private Limited
Raybros Medicaments has 3 directors on record. No former directors are listed.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Sarothi Roy | Director | 17 Apr 2018 | 8 Years 6 Months | Current |
| Madhumita Roy | Director | 17 Apr 2018 | 8 Years 6 Months | Current |
| Robin Sarothi Roy | Director | 17 Apr 2018 | 8 Years 6 Months | Current |
Peer comparison
Raybros Medicaments Private Limited is compared with the 6 companies closest to it by revenue in the Pharma industry (Pharma Retail and Distribution), with the same principal business activity (wholesale trading), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Globerian Pharma Private Limited | ₹2.75 Cr (FY 2025) | 5007.0% | Panchkula, Haryana, India | |||
| Cicerone Technologies Private Limited | ₹2.75 Cr (FY 2025) | 20.0% | Gurugram, Haryana, India | |||
| Poss Multitrade Private Limited | ₹2.75 Cr (FY 2022) | -42.0% | Mumbai, Maharashtra, India | |||
| Oviat Pharmaceuticals Private Limited | ₹2.74 Cr (FY 2024) | 53.0% | Jamshedpur, Jharkhand, India | |||
| Raybros Medicaments Private Limitedthis company | ₹2.74 Cr (FY 2024) | ₹10.79 Lakh | 3.9% | -2.0% | 16 | Mumbai, Maharashtra, India |
| Health Care (India) Limited | ₹2.73 Cr (FY 2024) | -98.0% | Chennai, Tamil Nadu, India | |||
| Elliott Labs Private Limited | ₹2.73 Cr (FY 2024) | 14.0% | Jaipur, Rajasthan, India |
To see the full peer comparison of Raybros Medicaments Private Limited, buy the company report.
Auditor
Raybros Medicaments Private Limited is audited by S S KAMAT & ASSOCIATES for the financial year 2021.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| S S KAMAT & ASSOCIATES | FY 2021 | 127282W |
Shareholding
The shareholding of Raybros Medicaments Private Limited is on record for FY 2021, split between promoters, domestic institutions, public shareholders and others.
| Shareholder category | FY 2021 |
|---|---|
| Promoters | |
| Domestic institutional investors (DII) | |
| Public | |
| Others |
To see the full shareholding pattern of Raybros Medicaments Private Limited, buy the company report.
Legal cases
No court or tribunal cases involving Raybros Medicaments Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Raybros Medicaments Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Employees & EPFO
Raybros Medicaments Private Limited has a workforce of 16 employees on its EPFO records as of Apr 04, 2024, across 1 active EPFO establishment.
GST
Raybros Medicaments has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AAICR8960K1ZN | Maharashtra | Active | 19 Mar 2019 |
To see the full GST registrations and return filing status of Raybros Medicaments Private Limited, buy the company report.
Recent activity
Raybros Medicaments Private Limited has 3 board changes on record since 2018: 3 appointments. The latest: Madhumita Roy was appointed as Director on 17 Apr 2018.
Frequently asked questions
Raybros Medicaments is an active private limited company based in Mumbai, Maharashtra, India. The company works in pharmaceutical retailers and distributors, within the pharma industry. It was incorporated on 17 April 2018 (8+ years old) and is registered under CIN U33100MH2018PTC308142.
Raybros Medicaments has 3 current directors:
- Sarothi Roy - Director
- Madhumita Roy - Director
- Robin Sarothi Roy - Director
The latest financial statements of Raybros Medicaments on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from FY 2019 are in the company report.
The GSTIN of Raybros Medicaments is 27AAICR8960K1ZN, registered in Maharashtra.
The CIN (Corporate Identification Number) of Raybros Medicaments is U33100MH2018PTC308142. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Raybros Medicaments was incorporated on 17 April 2018, making it 8+ years old. It is registered with the Registrar of Companies, Mumbai.
The peers of Raybros Medicaments by revenue are Globerian Pharma Private Limited, Cicerone Technologies Private Limited, Poss Multitrade Private Limited, Oviat Pharmaceuticals Private Limited, Health Care (India) Limited and 1 more, all in the Pharma industry (Pharma Retail and Distribution), with the same principal business activity (wholesale trading).
Madhumita Roy was appointed as Director on 17 Apr 2018. Robin Sarothi Roy was appointed as Director on 17 Apr 2018. Sarothi Roy was appointed as Director on 17 Apr 2018.
Yes, Raybros Medicaments is registered as a micro enterprise under Udyam registration (number: UDYAM-MH-18-0003264).
The registered office of Raybros Medicaments is at Gala No.12 Atlanta Estate Premises Co – Op Soc.Ltd. Vit Bhatti Goregaon Mulund Link Rd Gore, Gaon – East, Mumbai, Maharashtra, India – 400063.
Raybros Medicaments operates in the pharma industry, in the pharmaceutical retailers and distributors segment.